LTI 01

Drug Profile

LTI 01

Alternative Names: LTI-01

Latest Information Update: 03 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lung Therapeutics; University of Texas at Tyler
  • Class Antifibrotics; Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasminogen activator inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Empyema
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Empyema; Pleural effusion

Most Recent Events

  • 20 Jun 2018 Lung Therapeutics terminates phase I trial in Pleural effusion in Australia, New Zealand (Intrapleural), due to expiry of investigational product (ACTRN12616001442493p)
  • 14 Mar 2017 Phase-I clinical trials in Pleural effusion in Australia, New Zealand (Intrapleural) , ACTRN12616001442493p)
  • 14 Mar 2017 Phase-I clinical trials in Empyema in New Zealand, Australia (Intrapleural) (ACTRN12616001442493p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top